preclin
develop
research
potenti
middl
east
respiratori
syndrom
coronaviru
merscov
medic
countermeasur
remain
preliminari
advanc
need
countermeasur
readi
test
human
clinic
trial
research
prioriti
includ
standard
anim
model
viru
stock
studi
diseas
pathogenesi
efficaci
medic
countermeasur
develop
merscov
diagnost
improv
access
nonhuman
primat
support
preclin
research
studi
better
understand
control
merscov
diseas
includ
vaccin
studi
camel
develop
standard
clinic
trial
protocol
partner
clinic
trial
network
affect
countri
evalu
safeti
efficaci
investig
therapeut
strengthen
effort
identifi
success
medic
countermeasur
f
rom
septemb
april
total
laboratoryconfirm
middl
east
respiratori
syndrom
coronaviru
merscov
infect
lead
death
casefat
proport
report
world
health
organ
infect
identifi
saudi
arabia
zoonot
transmiss
exposur
merscovinfect
arabian
camel
known
dromedari
raw
milk
limit
nonsustain
humantohuman
transmiss
report
includ
larg
outbreak
healthcar
facil
recoveri
infecti
merscov
viru
cultur
specimen
bed
sheet
bedrail
intraven
fluid
hanger
radiograph
equip
indic
potenti
fomit
transmiss
viru
hospit
provid
care
merscov
patient
howev
sustain
humantohuman
transmiss
document
casepati
identifi
sourc
exposur
merscov
april
total
countri
report
local
acquir
export
case
arabian
peninsula
includ
case
unit
state
identifi
may
healthcar
personnel
becam
ill
work
saudi
arabia
travel
visit
saudi
arabia
qatar
unit
arab
emir
bahrain
return
south
korea
infect
merscov
trigger
merscov
case
result
death
multipl
health
facil
addit
case
person
travel
china
human
infect
merscov
expect
continu
occur
arabian
peninsula
preval
merscov
dromedari
cultur
import
camel
ie
food
milk
race
purpos
region
outbreak
sever
acut
respiratori
syndrom
sar
china
civet
cat
suspect
reservoir
sar
coronaviru
sarscov
cull
aggress
outbreak
identifi
contrast
cull
camel
cultur
impract
middl
east
merscov
zoonot
infect
human
continu
sinc
potenti
emerg
merscov
mutat
could
facilit
sustain
commun
transmiss
global
dissemin
predict
vaccin
specif
treatment
human
infect
sarscov
merscov
coronavirus
approv
sinc
effort
focus
further
develop
anim
model
vaccin
therapi
merscov
report
updat
current
state
develop
merscov
medic
countermeasur
includ
regulatori
challeng
unit
state
draw
attent
area
immedi
need
increas
infrastructur
support
develop
countermeasur
person
higher
risk
sever
diseas
includ
person
year
age
chronic
medic
condit
therapeut
drug
specif
activ
merscov
eg
antivir
drug
immunotherapeut
treatment
target
host
immun
respons
could
use
treatment
human
ill
caus
merscov
infect
preor
postexposur
prophylaxi
human
clinic
trial
potenti
merscov
medic
countermeasur
start
proofofconcept
data
must
obtain
vivo
studi
experiment
infect
anim
data
may
indic
product
potenti
efficaci
provid
mechan
select
avail
medic
countermeasur
candid
addit
merscov
vaccin
could
develop
anim
use
vaccin
dromedari
arabian
peninsula
sourc
countri
camel
import
horn
africa
reduc
merscov
transmiss
among
camel
possibl
camel
human
preclin
develop
merscov
medic
countermeasur
hinder
sever
factor
includ
limit
data
natur
histori
merscov
infect
human
lack
small
anim
model
natur
suscept
merscov
inabl
consist
replic
sever
human
diseas
merscovinfect
nonhuman
primat
nhp
anoth
factor
limit
access
clinic
sampl
recent
viru
isol
exampl
merscov
strain
isol
patient
rather
recent
isol
strain
current
use
investig
worldwid
small
anim
nhp
model
use
test
potenti
medic
countermeasur
efficaci
tabl
studi
mice
dipeptidyl
cluster
differenti
transduc
transgen
rabbit
hamster
ferret
review
elsewher
small
anim
model
use
screen
potenti
merscov
medic
countermeasur
major
nhp
model
develop
includ
rhesu
macaqu
common
marmoset
overal
common
marmoset
appear
better
suit
rhesu
macaqu
therapeut
studi
design
target
sever
diseas
marmoset
show
slightli
slower
onset
ill
longer
durat
sever
diseas
small
size
requir
lower
dose
therapeut
drug
howev
marmoset
model
standard
consist
laboratori
furthermor
size
marmoset
substanti
limit
sequenti
blood
sampl
virolog
pharmacokinet
test
challeng
develop
nhp
model
includ
determin
standard
optim
merscov
challeng
dose
volum
rout
exposur
well
limit
avail
nhp
especi
marmoset
larg
anim
model
develop
includ
camel
camelid
alpaca
model
may
vital
understand
virolog
immunolog
merscov
infect
dromedari
natur
host
addit
serolog
evid
merscov
infect
alpaca
report
qatar
major
gap
anim
model
includ
lack
consensu
avail
optim
anim
model
replic
sever
human
ill
merscov
infect
limit
avail
current
recent
circul
merscov
strain
lack
understand
clinic
relev
symptom
incorpor
clinic
score
use
signal
begin
treatment
anim
model
competit
fund
laboratori
space
avail
anim
expertis
emerg
reemerg
infecti
diseas
ebola
viru
diseas
zika
viru
diseas
secretari
us
depart
health
human
servic
declar
potenti
public
health
emerg
may
regard
merscov
infect
could
high
potenti
affect
nation
secur
health
secur
us
citizen
live
abroad
us
food
drug
administr
fda
subsequ
issu
emerg
use
author
center
diseas
control
prevent
cdc
vitro
molecular
diagnost
test
diagnos
merscov
infect
multipl
type
clinic
specimen
symptomat
patient
use
test
later
expand
includ
abil
test
asymptomat
contact
person
infect
merscov
travel
saudi
arabia
unit
state
cdc
made
test
avail
multipl
us
public
health
laboratori
us
depart
defens
laboratori
worldwid
although
test
distribut
extens
limit
term
cdc
abil
scale
suppli
reagent
support
surg
merscov
case
unit
state
countri
test
made
avail
therefor
emerg
use
author
issu
juli
commerci
develop
realstar
merscov
rtpcr
kit
us
altona
diagnost
gmbh
hamburg
germani
use
vitro
qualit
detect
merscov
rna
tracheal
aspir
tracheal
secret
sampl
although
commerci
assay
first
step
bridg
diagnost
test
avail
gap
case
surg
scenario
current
coverag
least
unit
state
insuffici
altern
fdaclear
commerci
test
avail
tabl
worldwid
gap
exist
lack
readili
avail
simpl
rapid
accur
diagnost
test
use
outpati
inpati
clinic
set
abil
facil
use
current
avail
higher
complex
molecular
test
limit
lack
commerci
develop
merscov
assay
may
partial
relat
limit
avail
clinic
specimen
merscov
isol
infect
patient
avail
serum
specimen
rtpcrconfirm
merscov
patient
surviv
help
facilit
develop
serolog
test
pair
acut
convalesc
serum
sampl
avail
serolog
test
use
confirm
merscov
infect
viral
shed
detect
surveil
purpos
measur
popul
exposur
immun
merscov
infect
investig
therapeut
drug
evalu
treatment
merscov
patient
prospect
random
control
clinic
trial
potenti
therapeut
drug
merscov
patient
includ
avail
approv
drug
nonspecif
properti
immunomodul
smallmolecul
drug
broad
antivir
activ
repurpos
fdaapprov
smallmolecul
drug
show
activ
merscov
vitro
tabl
newli
develop
monoclon
polyclon
antibodi
therapi
specif
activ
merscov
tabl
one
promis
approach
investig
librari
drug
approv
fda
european
medicin
agenc
consid
develop
time
manufactur
requir
new
product
repurpos
exist
drug
might
potenti
facilit
rapid
respons
outbreak
emerg
virus
see
regulatori
section
discuss
repurpos
earlystag
work
merscov
therapeut
includ
studi
focus
essenti
viral
replic
step
fusion
proteolysi
rna
polymer
tabl
immunotherapeut
evalu
consist
convalesc
plasma
monoclon
polyclon
antibodi
monoclon
antibodi
develop
specif
neutral
activ
merscov
spike
protein
platform
develop
rapidli
discov
monoclon
antibodi
either
fulli
human
convalesc
blood
transgen
anim
manufactur
larg
scale
like
good
safeti
profil
advanc
immunotherapeut
merscov
use
transchromosom
bovin
product
system
produc
fulli
human
polyclon
merscov
antibodi
phase
studi
product
recent
implement
http
preliminari
result
immunoprophylaxi
treatment
studi
shown
efficaci
fulli
human
monoclon
polyclon
antibodi
merscovinfect
mice
nhp
profil
defin
set
preclin
toxicolog
studi
challeng
develop
immunotherapeut
includ
ensur
absenc
antibodydepend
enhanc
diseas
reduc
risk
gener
escap
mutant
virus
would
resist
treatment
develop
merscov
candid
vaccin
initi
nation
institut
allergi
infecti
diseas
nation
institut
health
academ
investig
sever
compani
tabl
candid
vaccin
still
evalu
anim
model
gener
target
spike
protein
merscov
recombin
viru
subunit
dna
viruslik
vector
vaccin
one
liveattenu
merscov
candid
vaccin
earli
develop
preliminari
studi
sever
merscov
vaccin
candid
initi
earli
result
demonstr
immunogen
progress
nhp
challeng
phase
clinic
studi
adult
differ
dose
dna
plasmid
vaccin
express
merscov
spike
protein
start
januari
ongo
assess
antigen
evolut
circul
merscov
strain
essenti
inform
vaccin
develop
concern
must
address
develop
merscov
vaccin
potenti
caus
antibodydepend
enhanc
diseas
upon
viru
challeng
observ
sarscov
candid
vaccin
upon
sarscov
challeng
lack
preced
coronaviru
vaccin
human
pose
anoth
challeng
evalu
merscov
vaccin
human
although
vaccin
anim
coronavirus
safe
use
anim
consid
cultur
import
dromedari
arabian
peninsula
meat
milk
race
prevent
cameltocamel
merscov
transmiss
reduct
spread
dromedari
human
camel
vaccin
investig
govern
academ
commerci
investig
tabl
young
camel
appear
high
risk
merscov
infect
could
prioriti
group
vaccin
loss
matern
merscov
antibodi
month
birth
suggest
short
time
window
vaccin
major
challeng
approach
dromedari
reinfect
merscov
studi
farag
et
al
found
correl
merscov
rna
level
neutral
antibodi
camel
suggest
antibodi
may
protect
infect
older
camel
reinfect
camel
vaccin
strategi
may
requir
multipl
dose
booster
vaccin
increas
effect
unit
state
oversea
addit
dose
dna
vaccin
contain
merscov
spike
protein
induc
humor
immun
dromedari
recent
studi
modifi
vaccinia
viru
ankara
vaccin
express
merscov
spike
protein
administ
intranas
intramuscularli
dromedari
challeng
intranas
merscov
vaccin
dromedari
fewer
sign
respiratori
infect
lower
merscov
titer
upper
respiratori
tract
compar
unvaccin
dromedari
alpaca
new
world
camelid
investig
suitabl
proxi
camel
lack
avail
dromedari
unit
state
high
cost
acquir
dromedari
rel
smaller
size
alpaca
regulatori
consider
merscov
medic
countermeasur
unit
state
focus
pathway
human
clinic
trial
drug
vaccin
submiss
investig
new
drug
applic
investig
new
drug
submiss
must
adher
requir
set
forth
code
feder
regul
titl
part
cfr
http
wwwecfrgovcgibintextidx
tpl
sever
guidanc
document
exist
fda
websit
relat
virolog
microbiolog
pharmacolog
toxicolog
clinic
medic
consider
appropri
approv
pathway
like
productspecif
requir
consider
exist
product
data
propos
intend
use
popul
use
valid
endpoint
efficaci
predict
clinic
benefit
likewis
data
need
consider
emerg
use
author
includ
dose
find
dose
rang
durat
safeti
obtain
sourc
investig
new
drug
clinic
trial
repurpos
drug
approv
fda
ill
merscov
indic
potenti
expedit
acceler
mechan
action
antivir
activ
defin
chang
approv
final
drug
form
rout
administr
dose
exceed
current
approv
dose
durat
current
indic
popul
adequ
pharmacokinet
data
support
dose
riskbenefit
profil
accept
intend
popul
indic
exampl
riskbenefit
profil
approv
drug
oncolog
indic
may
unaccept
drug
repurpos
administr
healthi
popul
merscov
postexposur
prophylaxi
howev
data
requir
initi
human
trial
depend
characterist
drug
product
intend
use
merscov
sponsor
consid
priorit
drug
develop
basi
total
scientif
evid
merit
drug
alon
whether
drug
previous
approv
absenc
standard
accept
anim
model
simul
human
diseas
merscov
infect
unclear
fda
may
abl
expedit
licensur
approv
data
lack
best
approach
may
collect
preclin
safeti
data
implement
adapt
human
clinic
trial
approach
taken
medic
countermeasur
respons
ebola
viru
diseas
outbreak
diagnost
devic
current
emerg
use
author
pathway
serv
fast
approach
make
product
avail
emerg
public
health
purpos
emerg
termin
premarket
notif
product
submit
fda
thorough
evalu
k
http
wwwfdagov
emerg
infecti
diseas
wwwcdcgoveid
vol
juli
medicaldevicesproductsandmedicalproceduresdeviceap
overarch
goal
clinic
research
merscov
patient
optim
clinic
manag
identifi
effect
therapi
improv
surviv
although
clinic
data
merscov
patient
publish
case
seri
need
much
epidemiolog
clinic
virolog
immunolog
data
improv
limit
understand
pathogenesi
merscov
infect
human
gap
includ
inform
viral
load
durat
viral
shed
blood
urin
respiratori
clinic
specimen
infect
person
understand
innat
adapt
immun
respons
merscov
infect
patholog
data
distribut
merscov
respiratori
extrapulmonari
tissu
fatal
case
inform
autopsi
person
die
merscov
overal
improv
understand
pathogenesi
merscov
human
studi
investig
merscov
infect
autopsi
tissu
patient
die
diseas
collabor
especi
need
pool
systemat
collect
serial
clinic
specimen
merscov
patient
virolog
immunolog
biomark
analys
correl
clinic
ill
conduct
longterm
followup
survivor
sever
diseas
detail
understand
host
factor
cofactor
associ
diseas
sever
asymptomat
infect
fatal
ill
need
effort
promot
intern
share
clinic
specimen
merscov
isol
need
foster
develop
diagnost
therapeut
vaccin
use
standard
clinic
data
collect
instrument
common
biolog
sampl
protocol
serial
prospect
data
collect
facilit
data
pool
merscov
case
comparison
across
clinic
site
countri
global
collabor
among
clinic
network
also
need
implement
clinic
trial
prefer
random
control
clinic
trial
merscov
investig
therapeut
without
intern
agreement
protocol
systemat
standard
case
report
data
collect
method
haphazard
anecdot
report
analysi
diseas
cours
outcom
may
continu
intern
sever
acut
respiratori
emerg
infect
consortium
collabor
adapt
standard
protocol
control
clinic
trial
merscov
prospect
control
clinic
trial
ideal
random
clinic
trial
potenti
merscov
therapi
vaccin
human
need
urgent
howev
uncertainti
estim
timelin
develop
potenti
merscov
medic
countermeasur
need
character
exist
new
anim
model
unpredict
demonstr
favor
riskbenefit
outcom
preclin
test
competit
resourc
emerg
infecti
diseas
addit
risk
antibodydepend
enhanc
diseas
may
interrupt
timelin
conduct
human
clinic
trial
mer
cov
vaccin
immunotherapeut
research
potenti
merscov
medic
countermeasur
preclin
toxicolog
data
avail
initi
human
clinic
trial
although
anim
efficaci
data
technic
requir
implement
human
clinic
trial
potenti
countermeasur
data
consid
import
identifi
promis
medic
countermeasur
candid
justifi
risk
human
volunt
inform
design
futur
clinic
studi
timefram
product
specimen
panel
repositori
aid
commerci
diagnost
develop
also
conting
obtain
adequ
fund
clinic
sampl
although
preclin
develop
research
potenti
merscov
medic
countermeasur
achiev
appreci
progress
date
develop
preliminari
substant
challeng
must
overcom
potenti
countermeasur
readi
human
emerg
infecti
diseas
wwwcdcgoveid
vol
juli
result
substanti
progress
establish
infrastructur
platform
preclin
advanc
clinic
develop
countermeasur
serv
model
enabl
time
respons
emerg
infecti
diseas
global
public
health
concern
futur
